Blogs Archives - Wellthy Therapeutics

Category Archives: Blogs

Digital Solutions for Closing the Fertility Gap in Underserved Regions

Introduction Infertility affects numerous individuals globally, defined as the inability to conceive after a year of unprotected intercourse[1]. Beyond its medical scope, it carries emotional and societal burdens. The World Health Organization states that 17.5% of adults face infertility[2], highlighting its global impact. Despite medical advancements in infertility treatments, significant accessibility and affordability gaps persist,

Transforming CKD Management: Leveraging Digital Solutions for Enhanced Care and Patient Outcomes

Picture of adult hands holding a paper cutout of kidneys., Accompanied by the Title of the Position Paper: "Transforming CKD Management: Leveraging Digital Solutions for Enhanced Care and Patient Outcomes"

Abstract Chronic kidney disease (CKD) is a global health issue with increasing prevalence and significant associated morbidity and mortality. The burden of chronic disease is rapidly rising on a global scale. The management of the disease is complicated by comorbid conditions like hypertension, diabetes, and hyperlipidemia, which leaves unmet patient needs. The high symptom burden,

Revolutionizing Patient Care: Unleashing the Power of Digital Mechanisms of Action

Blog banner - Digital Mechanisms of Action

The integration of Digital Mechanisms of Action (DMoA) into healthcare systems has the potential to revolutionize patient care and significantly improve outcomes. DMoA leverages advanced technologies such as artificial intelligence, machine learning, predictive analytics, and big data to enhance various aspects of healthcare. Key Components of DMoA: Electronic Health Records (EHR): EHRs have transformed the

Wellthy Therapeutics adds Beyond Next Ventures as an investor; Expands into Japan

Wellthy Therapeutics Product Suite

Wellthy Therapeutics has secured additional financing, led by Beyond Next Ventures. This paves the way for Wellthy Therapeutics to expand its platform into the Japanese market, enabling enterprise customers to deploy world class digital health solutions to support their patients globally.

Enhancing Well-being and Symptom Management in Hemophilia: A Digital Behavioral Therapy Approach

This paper provides an in-depth analysis of Hemophilia, a rare genetic bleeding disorder that impedes the blood’s ability to clot, leading to spontaneous or post-injury bleeding. This condition manifests in physical challenges such as joint pain, swelling, stiffness, and potential neurological complications. The psychological ramifications of these physical symptoms often result in elevated levels of stress, anxiety, and depression.

Wellthy Therapeutics Announces Expansion into US with FDA & HIPAA Certifications

Wellthy Therapeutics, a global leader in digital health and digital therapeutics, announces the successful completion of its FDA 21 CFR Part 820, FDA 21 CFR Part 11, and HIPAA certification for its disease-agnostic, modular, software-as-a-medical-device (SaMD) platform. These international registrations further solidify the company’s commitment to maintaining the highest standards of data security, data privacy, quality and regulatory compliance in the development and manufacturing of digital health solutions for customers in the United States, and worldwide, and reinforce its leadership in the SaMD space.

DTx Asia Roundup


The first DTx Asia conference was held in Seoul, South Korea last week where experts engaged in dialogues surrounding the penetration, regulatory, and reimbursability environment around digital health solutions in the APAC region.  Wellthy’s CEO and Co-founder, Abhishek Shah, was a co-chair at the event and part of a panel on “How DTx companies plan

A discussion on the evolution of the DTx industry – from solutions to platforms DTx 1.0 to DTx 2.0

Digital therapeutics are taking off but are they meeting the needs of all stakeholders? Due to pharma’s vast size and their desire to ‘test and learn’ they often create multiple DTx ‘point solutions’ which leads to issues not just for themselves but also for other stakeholders. Patients  May have multiple comorbidities therefore experience ‘Digital poly-pharmacy’

Digital Therapeutics in PAH: Augmenting care journeys for patients with rare, complex chronic disease


Where Big Pharma Stands Recognizing this need, the major players in the PAH treatment space have added a digital solution to their portfolio. This first wave of solutions provide tracking of symptoms, education on the disease, interaction with devices such as nebulizers, and monitoring of emotional wellbeing. There is still an opportunity to go deeper

Lung Cancer: Addressing Gaps in Care for this Serious Non-Chronic Medical Condition Through Digital Therapeutics


Introduction More than half the people die within the first year of being diagnosed with Lung Cancer. The American Cancer Society’s estimates for lung cancer in the United States for 2022 are about 236,740 new cases and about 130,180 deaths. Lung Cancer is directly responsible for loss of income, increased health-related costs, morbidity, and mortality